Article

Thyroid disorder may heighten risk of glaucoma

Patients with glaucoma were 38% more likely to have had a thyroid disorder at some point in their lives than those without, according to a study published in the British Journal of Ophthalmology.

Birmingham, AL-Patients with glaucoma were 38% more likely to have had a thyroid disorder at some point in their lives than those without, according to a study published in the British Journal of Ophthalmology. Statistics were gathered from 12,376 people who participated in the 2002 National Health Interview Survey.

Participants were asked whether they ever had been diagnosed with a thyroid gland disorder or glaucoma. Slightly more than 4.5% of participants said glaucoma was diagnosed and 12% said a thyroid problem was diagnosed. The percentage of patients with glaucoma who said they had suffered a thyroid problem was 6.5% to 4.4% who had not.

An underactive thyroid can promote chemical deposits in the blood vessels serving the eye, which can spark an increase in IOP, said study authors.

Patients with thyroid problems should see an ophthalmologist or make their ophthalmologist aware of their thyroid condition, said lead researcher Gerald McGwin, PhD, vice chairman of the Department of Ophthalmology, University of Alabama School of Medicine, Birmingham.

"Somebody who has a history of thyroid problems and has not seen an ophthalmologist may have a heightened level of concern about their eyesight," he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.